SID.ir New Version

Paper Information

Journal:   INTERNATIONAL JOURNAL OF PEDIATRICS   april 2017 , Volume 5 , Number 4 (40); Page(s) 4723 To 4740.
 
Paper: 

Clinical Pharmacology Of Cefepime In Infants And Children

 
 
Author(s):  Pacifici Gian Maria*, Marchini Giovanna
 
* VIA SAN ANDREA 32, 56127 PISA, ITALY
 
Abstract: 
Cefepime is a fourth-generation cephalosporin which is approved in Europe and in the USA. Food and Drug Administration (FDA) approves cefepime in the treatment of febrile neutropenia. Cefepime is active against gram-negative microorganisms such as Escherichia coli, Haemophilus influenzae, Enterobacter, Klebsiella, Morganella, Neisseria, Serratia, and Proteus species. Cefepime is also active against gram-positive microorganisms such as Streptococcus pneumoniae, Streptococcus agalactiae, and Staphylococcus aureus. Cefepime binds to plasma proteins ≤ 20%, and it is excreted unchanged in the urine. Cefepime distributes widely in body tissues and fluids such as cerebrospinal fluid, bile, bronchial secretions, ascites fluid, and middle ear. In neonates, the half-life of cefepime ranges from 3. 59+0. 61 and 5. 09+1. 80 hours, and in adults it is 2. 1 (range, 1. 3 to 2. 4 hours). The rank order of the top 10 pediatric pathogens was analyzed and the comparative antimicrobial potency of broad-spectrum parenteral cephalosporins was exterminated. The rank order of the top 10 pediatric pathogens was Streptococcus pneumoniae (15. 5%) > Haemophilus influenzae (14. 6%) > Staphylococcus aureus (13. 8%) > Moraxella catarrhalis = coagulase-negative staphylococci (8. 0%) > Escherichia coli (7. 8%) > Pseudomonas aeruginosa (5. 2%) > Klebsiella spp. (4. 8%) > Enterococcus spp. (4. 7%) > beta-hemolytic streptococci (4. 4%). Cefepime is the most active antibiotic among β-lactams. Cefepime is active against Enterobacter species (MIC90), 2 μ g/ml; 99. 3% susceptible, whereas the susceptibility rates of other broad-spectrum β-lactams (ceftriaxone, ceftazidime and piperacillin-tazobactam), were significantly lower (78. 4 to 81. 5). Cefepime remains a very potent alternative for the treatment of contemporary pediatric infections. The aim of the present study was to review the clinical pharmacology of cefepime in infants and children.
 
Keyword(s): Cefepime,Dosage,Effects,Pharmacokinetics,Resistance
 
 
International related papers: 
 
Most related Highly related Moderately related Least related
 
References: 
  • Not Registered.
  •  
  •  
 
Citations: 
  • Not Registered.
 
+ Click to Cite.
APA: Copy

PACIFICI, G., & Marchini, G. (2017). Clinical Pharmacology of Cefepime in Infants and Children. INTERNATIONAL JOURNAL OF PEDIATRICS, 5(4 (40)), 4723-4740. https://www.sid.ir/en/journal/ViewPaper.aspx?id=662952



Vancouver: Copy

PACIFICI GIAN MARIA, Marchini Giovanna. Clinical Pharmacology of Cefepime in Infants and Children. INTERNATIONAL JOURNAL OF PEDIATRICS. 2017 [cited 2022August08];5(4 (40)):4723-4740. Available from: https://www.sid.ir/en/journal/ViewPaper.aspx?id=662952



IEEE: Copy

PACIFICI, G., Marchini, G., 2017. Clinical Pharmacology of Cefepime in Infants and Children. INTERNATIONAL JOURNAL OF PEDIATRICS, [online] 5(4 (40)), pp.4723-4740. Available: https://www.sid.ir/en/journal/ViewPaper.aspx?id=662952.



 
  pdf-File
Yearly Visit 35
 
 
Latest on Blog
Enter SID Blog